Literature DB >> 24144874

Reduced axonal motor protein expression in non-lesional grey matter in multiple sclerosis.

K Hares1, K Kemp2, C Rice2, E Gray2, N Scolding2, A Wilkins2.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is a neurological disease characterised by central nervous system inflammation, demyelination, axonal degeneration and neuronal injury. Preventing neuronal and axon damage is of paramount importance in attempts to prevent disease progression. Intact axonal transport mechanisms are crucial to axonal integrity and evidence suggests these mechanisms are disrupted in MS. Anterograde axonal transport is mediated to a large extent through the kinesin superfamily proteins. Recently, certain kinesin superfamily proteins (KIF5A, KIF1B and KIF21B) were implicated in MS pathology.
OBJECTIVES: To investigate the expression of KIF5A, KIF21B and KIF1B in MS and control post-mortem grey matter.
METHODS: Using both quantitative real-time polymerase chain reaction (PCR) and Immunodot-blots assays, we analysed the expression of kinesin superfamily proteins in 27 MS cases and 13 control cases not linked to neurological disease.
RESULTS: We have shown significant reductions in KIF5A, KIF21B and KIF1B messenger ribonucleic acid (mRNA) expression and also KIF5A protein expression in MS grey matter, as compared to control grey matter.
CONCLUSION: We have shown significant reductions in mRNA and protein levels of axonal motor proteins in the grey matter of MS cases, which may have important implications for the pathogenesis of neuronal/axonal injury in the disease.
© The Author(s) 2013.

Entities:  

Keywords:  Axonal injury; KIF1B; KIF21B; KIF5A; axonal transport; grey matter; kinesin; multiple sclerosis; protein expression

Mesh:

Substances:

Year:  2013        PMID: 24144874     DOI: 10.1177/1352458513508836

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

Review 1.  Neurodegeneration in Progressive Multiple Sclerosis.

Authors:  Graham Campbell; Don Mahad
Journal:  Cold Spring Harb Perspect Med       Date:  2018-10-01       Impact factor: 6.915

Review 2.  Thalamus pathology in multiple sclerosis: from biology to clinical application.

Authors:  Markus Kipp; Nina Wagenknecht; Cordian Beyer; Sebastian Samer; Jens Wuerfel; Omid Nikoubashman
Journal:  Cell Mol Life Sci       Date:  2014-11-23       Impact factor: 9.261

3.  Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes.

Authors:  Weston W Blakeslee; Ying-Hsi Lin; Matthew S Stratton; Philip D Tatman; Tianjing Hu; Bradley S Ferguson; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2017-09-05       Impact factor: 5.000

4.  KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis.

Authors:  Kelly Hares; K Kemp; S Loveless; C M Rice; N Scolding; E Tallantyre; N Robertson; A Wilkins
Journal:  J Neurol       Date:  2021-01-23       Impact factor: 4.849

5.  Reductions in kinesin expression are associated with nitric oxide-induced axonal damage.

Authors:  Juliana Redondo; Kelly Hares; Alastair Wilkins; Neil Scolding; Kevin Kemp
Journal:  J Neurosci Res       Date:  2015-01-29       Impact factor: 4.164

6.  Immunohistochemical and transcriptome analyses indicate complex breakdown of axonal transport mechanisms in canine distemper leukoencephalitis.

Authors:  Ingo Spitzbarth; Charlotte Lempp; Kristel Kegler; Reiner Ulrich; Arno Kalkuhl; Ulrich Deschl; Wolfgang Baumgärtner; Frauke Seehusen
Journal:  Brain Behav       Date:  2016-05-03       Impact factor: 2.708

Review 7.  Experimental autoimmune encephalomyelitis from a tissue energy perspective.

Authors:  Roshni A Desai; Kenneth J Smith
Journal:  F1000Res       Date:  2017-11-08

Review 8.  Changes in Deoxyribonucleic Acid Methylation Contribute to the Pathophysiology of Multiple Sclerosis.

Authors:  Naiara Celarain; Jordi Tomas-Roig
Journal:  Front Genet       Date:  2019-11-12       Impact factor: 4.599

9.  Normal levels of KIF5 but reduced KLC1 levels in both Alzheimer disease and Alzheimer disease in Down syndrome: evidence suggesting defects in anterograde transport.

Authors:  Xu-Qiao Chen; Utpal Das; Gooho Park; William C Mobley
Journal:  Alzheimers Res Ther       Date:  2021-03-10       Impact factor: 6.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.